Your browser is no longer supported. Please, upgrade your browser.
VTGN VistaGen Therapeutics, Inc. daily Stock Chart
VistaGen Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.60 Insider Own- Shs Outstand9.13M Perf Week5.20%
Market Cap16.62M Forward P/E- EPS next Y-0.90 Insider Trans- Shs Float7.60M Perf Month1.68%
Income-11.60M PEG- EPS next Q-0.47 Inst Own22.30% Short Float1.43% Perf Quarter-7.61%
Sales1.30M P/S12.78 EPS this Y94.70% Inst Trans- Short Ratio2.24 Perf Half Y-20.87%
Book/sh0.07 P/B26.00 EPS next Y50.30% ROA-183.30% Target Price17.00 Perf Year-44.00%
Cash/sh0.32 P/C5.73 EPS next 5Y- ROE-346.00% 52W Range1.60 - 4.69 Perf YTD-51.21%
Dividend- P/FCF- EPS past 5Y37.80% ROI- 52W High-61.19% Beta-0.72
Dividend %- Quick Ratio2.50 Sales past 5Y-1.40% Gross Margin- 52W Low13.75% ATR0.14
Employees10 Current Ratio2.50 Sales Q/Q- Oper. Margin- RSI (14)49.97 Volatility9.01% 8.28%
OptionableNo Debt/Eq0.17 EPS Q/Q92.70% Profit Margin- Rel Volume0.55 Prev Close1.77
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume48.51K Price1.82
Recom2.00 SMA20-2.47% SMA50-1.40% SMA200-28.30% Volume26,540 Change2.82%
Mar-28-17Initiated Maxim Group Buy $4
Aug-14-17 04:05PM  VistaGen Therapeutics Reports First Fiscal Quarter 2018 Financial Results and Provides Business Update Marketwired
Aug-08-17 08:30AM  VistaGen Receives Notice of Allowance from U.S. Patent and Trademark Office for U.S. Patent regarding Breakthrough Methods for Producing Blood Cells, Platelets and Bone Marrow Stem Cells with Potential to Treat Autoimmune Disorders and Cancer Marketwired +5.11%
Jul-10-17 08:30AM  VistaGen Therapeutics Appoints Dr. Mark Wallace to Clinical Advisory Board to Advance AV-101 as a Potential Non-Opioid Treatment for Neuropathic Pain Marketwired +6.08%
Jun-29-17 08:30AM  VistaGen Therapeutics Reports Fiscal 2017 Financial Results and Provides Corporate Update Marketwired
Jun-22-17 08:30AM  VistaGen Announces Peer-Reviewed Publication in the Scandinavian Journal of Pain Highlighting Orally-Available AV-101's Excellent Safety Profile and Potential as a Non-Opioid Treatment for Neuropathic Pain Marketwired
May-01-17 08:00AM  VistaGen Therapeutics' Largest Stockholder Signs 6-Month Lock-Up Agreement Marketwired +12.12%
Apr-27-17 09:00AM  VistaGen Therapeutics Announces Peer-Reviewed Publication in The Journal of Pain Highlighting AV-101's Potential for Treating Neuropathic Pain Marketwired
Mar-29-17 04:18PM  VISTAGEN THERAPEUTICS, INC. Files SEC form 8-K, Other Events +11.96%
09:00AM  VistaGen Therapeutics Receives European Patent Office Notice of Intention to Grant European Patent for AV-101 Marketwired
Mar-28-17 07:44AM  Coverage initiated on VistaGen by Maxim Group
Mar-10-17 03:17PM  VistaGen Therapeutics Inc. (Nasdaq: VTGN) to Ring The Nasdaq Stock Market Closing Bell GlobeNewswire
Mar-08-17 09:00AM  VistaGen Therapeutics to Ring the Nasdaq Stock Market Closing Bell on Monday, March 13, 2017 Marketwired -5.24%
Feb-17-17 01:04PM  VISTAGEN THERAPEUTICS, INC. Financials
Feb-13-17 04:31PM  VISTAGEN THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
04:15PM  VistaGen Therapeutics Reports Fiscal Third Quarter 2017 Financial Results and Provides Corporate Update Marketwired
Jan-10-17 01:50PM  Vistagen Therapeutics Inc (VTGN) Finds Stem Cell Partner In Bayer AG (ADR) (BAYRY) With Phase II TRD Data On Tap Insider Monkey
01:50PM  Vistagen Therapeutics Inc (VTGN) Finds Stem Cell Partner In Bayer AG (ADR) (BAYRY) With Phase II TRD Data On Tap at Insider Monkey
Jan-05-17 09:33AM  VistaGen Therapeutics to Present at Biotech Showcase 2017 PR Newswire
Dec-14-16 08:01AM  VISTAGEN THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events -6.32%
07:05AM  VistaGen Therapeutics Grants Exclusive Sublicense of Cardiac Stem Cell Technologies to BlueRock Therapeutics PR Newswire
Nov-30-16 07:05AM  VistaGen Therapeutics to Present at 9th Annual LD Micro Main Event PR Newswire
Nov-22-16 03:22PM  Small-Cap Biotech Is on Front Lines of Fight Against Depression
Nov-15-16 06:25AM  VISTAGEN THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
Nov-14-16 05:24PM  VISTAGEN THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition
04:15PM  VistaGen Therapeutics Reports Second Quarter 2017 Financial Results and Business Update PR Newswire
Oct-21-16 05:04PM  VISTAGEN THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Oct-04-16 07:00AM  VistaGen Therapeutics Appoints Mark A. McPartland Vice President of Corporate Development and Investor Relations PR Newswire
Sep-27-16 05:16PM  VISTAGEN THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing product candidates for patients with central nervous system (CNS) diseases. The company's lead product candidate, AV-101, which is in Phase IIa development as a augmentation option for adult patients suffering from treatment-resistant major depressive disorder (TRD). It also focuses on potential commercial applications of its human pluripotent stem cell (hPSC) technology platform, including drug rescue to develop proprietary small molecule new chemical entities (NCEs) for its internal drug candidate pipeline; and regenerative medicine (RM) using blood, cartilage, heart, and/or liver cells derived from hPSCs. In addition, the company offers CardioSafe 3D, an in vitro cardiac bioassay system for predicting human heart toxicity of small molecule NCEs. It has strategic collaborations with University Health Network, the McEwen Centre for Regenerative Medicine, and the Centre for the Commercialization of Regenerative Medicine for stem cell technology research, development, and cell production; and Norac Pharma, Pharmatek, and Synterys, Inc. to design, produce, and analyze AV-101 clinical trial materials and potential drug rescue NCEs. The company also has strategic relationships with Pharmaceutical Product Development, LLC; Cato Research, Ltd.; and Massachusetts General Hospital Clinical Trials Network and Institute for regulatory expertise and clinical development support. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.